Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Rudy Saucillo who wrote (950)	12/29/1998 12:39:00 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 1477

Rudy: I remember reading that statement: "Scios has pointed out that the greater incidence of mortality has not been directly tied to Fiblast use." If it is not drug related, than why it was discontinued? No benefit? SCIO mentioned that Euro trials is 24 hr i.v. infusion versus 8 hr in NA, so maybe outcome will be better, but I am skeptical here. For the sake of the stroke victims (not for my investment) I wish that drug work. Still, my view is that stroke is not FIBLAST right application. CAD/PVD should be right one, so maybe at H&Q Scios will report results on this trial. Also, I expect some more details from two PIII Natrecor aCHF trials. Hope will bring more confidence in NATRECOR, right on time for FDA AC meeting. Miljenko